Johnson & Johnson (JNJ) Stock Price

Johnson & Johnson Price

NYSE·CLOSED
255.97USD-11.24 (-4.30 %)
Market closed

Over the last 19 years Johnson & Johnson grew revenue by 3.0% annually, reaching 94.19 B USD. Earnings per share have grown at 5.8% per year over the last 19 years. For Johnson & Johnson, the net margin of 28.5% is up versus 26.5% a few years ago. At today's price the dividend yield works out to roughly 2.01%. The payout ratio is around 47% of earnings. The dividend has grown at 6.9% per year over the past 19 years. The consensus 12-month price target for Johnson & Johnson is 241.74 USD, about 5.6% below where the stock trades today. Of 32 analysts, 19 rate the stock a buy — an overall Buy consensus. The stock trades about 55% above its 52-week low.

Johnson & Johnson stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Johnson & Johnson over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Johnson & Johnson stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Johnson & Johnson's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Johnson & Johnson Stock Price History
DateJohnson & Johnson Price
7/31/2026255.97 USD
7/29/2026267.21 USD
7/27/2026267.01 USD
7/23/2026259.27 USD
7/22/2026255.63 USD
7/21/2026250.61 USD
7/20/2026248.82 USD
7/17/2026253.04 USD
7/16/2026249.97 USD
7/15/2026247.02 USD
7/14/2026253.85 USD
7/13/2026258.16 USD
7/10/2026256.98 USD
7/9/2026259.10 USD
7/8/2026267.21 USD
7/7/2026267.24 USD
7/6/2026258.52 USD
7/2/2026263.04 USD
7/1/2026253.98 USD
6/30/2026253.97 USD
6/29/2026256.62 USD
6/26/2026254.66 USD
6/25/2026244.88 USD
6/24/2026241.00 USD
6/23/2026239.08 USD
6/22/2026230.60 USD
6/18/2026228.52 USD
6/17/2026233.46 USD
6/16/2026233.15 USD
6/15/2026237.46 USD
6/12/2026239.62 USD
6/11/2026240.90 USD
6/10/2026238.70 USD
6/9/2026237.00 USD
6/8/2026232.16 USD
6/5/2026232.08 USD
6/4/2026226.87 USD
6/3/2026223.39 USD
6/2/2026223.04 USD
6/1/2026221.78 USD
5/29/2026227.95 USD
5/28/2026230.60 USD
5/27/2026232.20 USD
5/26/2026229.76 USD
5/22/2026233.92 USD
5/21/2026229.32 USD
5/20/2026230.10 USD
5/19/2026230.00 USD
5/18/2026228.92 USD
5/15/2026226.71 USD
5/14/2026230.80 USD
5/13/2026230.42 USD
5/12/2026224.26 USD
5/11/2026221.43 USD
5/8/2026221.32 USD
5/7/2026222.51 USD
5/6/2026224.62 USD
5/5/2026225.55 USD
5/4/2026224.20 USD
5/1/2026227.19 USD
4/30/2026229.85 USD
4/29/2026227.35 USD
4/28/2026227.79 USD
4/27/2026225.34 USD
4/24/2026227.50 USD
4/23/2026230.65 USD
4/22/2026226.10 USD
4/21/2026226.16 USD
4/20/2026230.69 USD
4/17/2026234.18 USD
4/16/2026234.54 USD
4/15/2026238.67 USD
4/14/2026240.10 USD
4/13/2026237.96 USD
4/10/2026238.46 USD
4/9/2026241.31 USD
4/8/2026241.30 USD
4/7/2026238.41 USD
4/6/2026240.97 USD
4/2/2026243.04 USD
4/1/2026244.12 USD
3/31/2026244.44 USD
3/30/2026242.49 USD
3/27/2026240.45 USD
3/26/2026239.24 USD
3/25/2026239.93 USD
3/24/2026235.27 USD
3/23/2026235.42 USD
3/20/2026235.37 USD
3/19/2026237.60 USD
3/18/2026237.28 USD
3/17/2026238.11 USD
3/16/2026243.19 USD
3/13/2026241.52 USD
3/12/2026242.04 USD
3/11/2026242.99 USD
3/10/2026243.71 USD
3/9/2026242.59 USD
3/6/2026240.40 USD
3/5/2026239.63 USD
3/4/2026245.30 USD
3/3/2026246.75 USD
3/2/2026248.56 USD
2/27/2026248.43 USD
2/26/2026243.47 USD
2/25/2026245.17 USD
2/24/2026246.28 USD
2/23/2026245.84 USD
2/20/2026242.49 USD
2/19/2026246.91 USD
2/18/2026244.99 USD
2/17/2026243.33 USD
2/13/2026243.45 USD
2/12/2026244.55 USD
2/11/2026240.86 USD
2/10/2026238.35 USD
2/9/2026238.64 USD
2/6/2026239.99 USD
2/5/2026237.79 USD
2/4/2026234.47 USD
2/3/2026233.10 USD
2/2/2026230.75 USD
1/30/2026227.25 USD
1/29/2026227.29 USD
1/28/2026227.72 USD
1/27/2026224.44 USD
1/26/2026221.49 USD
1/23/2026220.14 USD
1/22/2026218.49 USD
1/21/2026218.01 USD
1/20/2026218.21 USD
1/16/2026218.66 USD
1/15/2026219.57 USD
1/14/2026218.55 USD
1/13/2026213.65 USD
1/12/2026209.72 USD
1/9/2026204.39 USD
1/8/2026205.75 USD
1/7/2026207.49 USD
1/6/2026204.79 USD
1/5/2026204.31 USD
1/2/2026207.35 USD
12/31/2025206.95 USD
12/30/2025206.91 USD
12/29/2025207.56 USD
12/26/2025207.63 USD
12/24/2025207.78 USD
12/23/2025205.78 USD
12/22/2025207.32 USD
12/19/2025206.37 USD
12/18/2025208.31 USD
12/17/2025210.33 USD
12/16/2025209.30 USD
12/15/2025214.17 USD
12/12/2025211.58 USD
12/11/2025210.01 USD
12/10/2025206.54 USD
12/9/2025199.96 USD
12/8/2025201.62 USD
12/5/2025201.93 USD
12/4/2025202.48 USD
12/3/2025205.33 USD
12/2/2025205.42 USD
12/1/2025205.34 USD
11/28/2025206.92 USD
11/26/2025207.56 USD
11/25/2025206.67 USD
11/24/2025206.05 USD
11/21/2025203.90 USD
11/20/2025203.07 USD
11/19/2025202.51 USD
11/18/2025200.00 USD
11/17/2025199.58 USD
11/14/2025195.93 USD
11/13/2025195.25 USD
11/12/2025194.39 USD
11/11/2025193.83 USD
11/10/2025188.41 USD
11/7/2025186.57 USD
11/6/2025186.97 USD
11/5/2025186.00 USD
11/4/2025186.86 USD
11/3/2025186.26 USD
10/31/2025188.87 USD
10/30/2025189.05 USD
10/29/2025186.60 USD
10/28/2025186.93 USD
10/27/2025190.30 USD
10/24/2025190.40 USD
10/23/2025192.47 USD
10/22/2025192.94 USD
10/21/2025191.88 USD
10/20/2025193.72 USD
10/17/2025193.22 USD
10/16/2025192.12 USD
10/15/2025191.17 USD
10/14/2025190.85 USD
10/13/2025190.90 USD
10/10/2025190.72 USD
10/9/2025191.08 USD
10/8/2025189.69 USD
10/7/2025188.89 USD
10/6/2025188.16 USD
10/3/2025188.64 USD
10/2/2025185.98 USD
10/1/2025186.05 USD
9/30/2025185.42 USD
9/29/2025181.62 USD
9/26/2025179.71 USD
9/25/2025177.73 USD
9/24/2025176.69 USD
9/23/2025176.58 USD
9/22/2025174.21 USD
9/19/2025176.19 USD
9/18/2025174.16 USD
9/17/2025177.20 USD
9/16/2025176.46 USD
9/15/2025177.40 USD
9/12/2025178.06 USD
9/11/2025178.50 USD
9/10/2025175.79 USD
9/9/2025176.96 USD
9/8/2025178.13 USD
9/5/2025178.43 USD
9/4/2025178.76 USD
9/3/2025178.00 USD
9/2/2025178.06 USD
8/29/2025177.17 USD
8/28/2025175.45 USD
8/27/2025176.79 USD
8/26/2025176.49 USD
8/25/2025178.41 USD
8/22/2025179.29 USD
8/21/2025178.93 USD
8/20/2025178.84 USD
8/19/2025177.80 USD
8/18/2025176.25 USD
8/15/2025176.64 USD
8/14/2025174.72 USD
8/13/2025174.42 USD
8/12/2025172.78 USD
8/11/2025173.82 USD
8/8/2025173.33 USD
8/7/2025171.53 USD
8/6/2025170.59 USD
8/5/2025170.74 USD
8/4/2025171.04 USD
8/1/2025167.33 USD
7/31/2025164.74 USD
Access this data via the Eulerpool API
Get Free API Key

Johnson & Johnson Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
85.16 B USD
21.85 B USD
35.15 B USD
Jan 1, 2024
88.82 B USD
22.15 B USD
14.07 B USD
Jan 1, 2025
94.19 B USD
25.60 B USD
26.80 B USD
Jan 1, 2026 (e)
101.27 B USD
24.91 B USD
28.38 B USD
Jan 1, 2027 (e)
108.58 B USD
26.71 B USD
31.28 B USD
Jan 1, 2028 (e)
116.93 B USD
28.76 B USD
34.84 B USD
Jan 1, 2029 (e)
124.85 B USD
30.71 B USD
39.21 B USD
Jan 1, 2030 (e)
134.04 B USD
32.97 B USD
43.62 B USD

Johnson & Johnson Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 31, 2026, 2:19 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESB
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
70.0771.8976.4581.5882.0682.5878.7479.9985.1688.8294.19101.27108.58116.93124.85134.04
-5.732.596.346.710.590.64-4.651.596.464.306.057.517.227.696.777.36
69.2769.6966.7266.7966.4265.5870.2869.2568.5969.0772.7872.7872.7872.7872.7872.78
48.5450.1051.0154.4954.5054.1655.3455.3958.4161.3568.5673.7179.0385.1190.8797.56
18.2920.8918.9021.1820.9719.7320.9421.0121.8522.1525.6024.9126.7128.7630.7132.97
26.1029.0624.7225.9625.5523.8926.6026.2725.6624.9427.1724.6024.6024.6024.6024.60
15.4116.541.3015.3015.1214.7120.8817.9435.1514.0726.8028.3831.2834.8439.2143.62
-5.607.34-92.141,076.69-1.16-2.6841.89-14.0795.94-59.9990.565.8910.2011.3812.5411.25
2.953.153.323.543.753.984.194.454.704.915.145.205.475.76––
6.886.785.406.635.936.135.286.215.624.474.681.175.195.30––
2.802.762.682.722.672.672.672.662.432.432.442.442.442.442.442.44
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Johnson & Johnson generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Johnson & Johnson retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Johnson & Johnson's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Johnson & Johnson has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Johnson & Johnson's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Johnson & Johnson stock margins

The Johnson & Johnson margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Johnson & Johnson. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Johnson & Johnson.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
70.28 %
26.60 %
26.52 %
Jan 1, 2022
69.25 %
26.27 %
22.43 %
Jan 1, 2023
68.59 %
25.66 %
41.28 %
Jan 1, 2024
69.07 %
24.94 %
15.84 %
Jan 1, 2025
72.78 %
27.17 %
28.46 %
Jan 1, 2026 (e)
72.78 %
24.60 %
28.03 %
Jan 1, 2027 (e)
72.78 %
24.60 %
28.81 %
Jan 1, 2028 (e)
72.78 %
24.60 %
29.80 %

Johnson & Johnson Stock Revenue, EBIT, Earnings per Share

The Johnson & Johnson earnings per share therefore indicates how much revenue Johnson & Johnson has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
29.49 USD
7.84 USD
7.82 USD
Jan 1, 2022
30.03 USD
7.89 USD
6.73 USD
Jan 1, 2023
35.03 USD
8.99 USD
14.46 USD
Jan 1, 2024
36.60 USD
9.13 USD
5.80 USD
Jan 1, 2025
38.62 USD
10.49 USD
10.99 USD
Jan 1, 2026 (e)
41.69 USD
10.21 USD
11.68 USD
Jan 1, 2027 (e)
44.70 USD
10.95 USD
12.88 USD
Jan 1, 2028 (e)
48.13 USD
11.79 USD
14.34 USD

Johnson & Johnson business model & stock analysis

Johnson & Johnson is an American company that was founded in 1886 by the brothers Robert, James, and Edward Johnson. The company is headquartered in New Brunswick, New Jersey, USA and is now an internationally operating company with more than 130,000 employees worldwide. The history of Johnson & Johnson began with the production of medical bandages. In 1887, the first self-adhesive wound plaster was invented and patented. In the following years, the product range was significantly expanded and now includes a wide range of health products. This includes pharmaceuticals, medical devices, hygiene products, personal care products, and baby products. The business model of Johnson & Johnson is to improve the lives of people worldwide. The company places great importance on innovation, quality, and sustainability. With its long-standing experience and expertise in the healthcare industry, Johnson & Johnson is able to understand the needs of customers and offer products tailored to their specific needs. Johnson & Johnson is now active in three main business areas: Consumer Health, Medical Devices and Diagnostics, and Pharmaceuticals. Within these business areas, there are a variety of brands and products that are among the most well-known in the world. The Consumer Health division of Johnson & Johnson is focused on the production of health and personal care products for consumers. Some well-known brands in this area include Listerine, Johnson's Baby, Neutrogena, and Nicorette. The company offers a wide range of products, from cold and allergy medications to skincare products and toothpastes. Medical Devices and Diagnostics is another major business area of Johnson & Johnson. The company is a leading provider of medical devices and diagnostic products worldwide. Products in this area include surgical systems, implantable devices, diagnostic tests, and imaging devices. Well-known brands in this area include Ethicon, Depuy Synthes, and Cordis. Pharmaceuticals is the third major business area of Johnson & Johnson. The company develops and produces innovative pharmaceuticals for the treatment of diseases such as cancer, diabetes, heart disease, and neurological disorders. Some well-known brands in this area include Remicade, Invega, and Zytiga. Johnson & Johnson is also known for its commitment to sustainability and corporate social responsibility. The company is committed to having a positive impact on the environment and the communities in which it operates. For example, Johnson & Johnson aims to reduce its CO2 emissions by 60% by 2030. Overall, Johnson & Johnson is a leading healthcare company focused on providing innovative and high-quality products that improve the lives of people worldwide. With a wide range of brands and products in various business areas, the company is well positioned to continue to be successful in the future.

Johnson & Johnson SWOT Analysis

Strengths

Johnson & Johnson (J&J) possesses several key strengths that contribute to its success in the market. Firstly, the company has a diversified product portfolio spanning various sectors such as healthcare, pharmaceuticals, and consumer goods. This diversification allows J&J to leverage its brand equity and penetrate multiple markets effectively.

Secondly, J&J has a strong brand reputation built on trust and reliability. The company is known for its high-quality products, which have earned consumer loyalty over the years. This positive brand perception gives J&J a competitive edge and enhances customer trust, leading to continued business growth.

Additionally, J&J has a vast global presence, operating in multiple countries around the world. This global reach provides the company with access to diverse markets and a broad customer base. It enables J&J to adapt to changing market dynamics and explore new growth opportunities.

Weaknesses

Despite its strengths, J&J also faces some notable weaknesses. One of the main weaknesses is its dependence on external suppliers for raw materials and components. Any disruption in the supply chain could impact production and result in delays or shortages of J&J products.

Furthermore, J&J has experienced product recalls and legal issues in the past, which have affected its reputation and financial performance. These incidents highlight a need for stricter quality control measures and regulatory compliance within the organization.

Opportunities

J&J has several opportunities to capitalize on in the market. One notable opportunity is the growing demand for healthcare and pharmaceutical products, driven by an aging population and increasing healthcare needs globally. J&J can leverage its expertise and expand its product offerings to cater to these emerging market needs.

Additionally, advancements in technology and digitalization present opportunities for J&J to enhance its product innovation and delivery channels. Embracing digital platforms and integrating technology in its operations can help the company stay competitive and meet changing customer preferences.

Threats

J&J needs to be aware of several potential threats that may impact its business. One significant threat is increasing competition from both established players and new entrants in the healthcare and pharmaceutical industries. This competition may affect market share and profitability.

Moreover, evolving regulations and policies in the healthcare sector pose a threat to J&J's operations. Compliance with stricter regulations can increase costs and restrict product development and distribution processes.

Additionally, the current global economic environment and geopolitical uncertainties may impact consumer spending patterns, which could result in lower demand for J&J products.

Johnson & Johnson Segments

Johnson & Johnson Revenue by Segment (1/6)

  • 3 Years

  • 5 Years

  • Max

DARZALEX
Stelara
OTC
ELECTROPHYSIOLOGY
GENERAL
Tremfya
ADVANCED
Remicade
Skin health/Beauty
CONTACT LENSES/OTHER
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA
ERLEADA
IMBRUVICA
SPINE & OTHER
TRAUMA
SPINE,SPORTS & OTHER
ZYTIGA
Simponi/Simponi Aria
XARELTO
OPSUMIT
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
UPTRAVI
CARVYKTI
Abiomed
SPRAVATO
Baby Care
HIPS
OTHER NEUROSCIENCE
KNEES
SURGICAL
Oral Care
EDURANT/rilpivirine
Other
Shockwave Medical, Inc
Women's Health
PROCRIT/EPREX
VELCADE
Other Oncology
INVOKANA/INVOKAMET
RYBREVANT/LAZCLUZE
Wound Care and Other
CAPLYTA
CONCERTA/Methylphenidate
RISPERDAL CONSTA
TECVAYLI
ZYTIGA/abiraterone acetate
TALVEY
Other Infectious Diseases
other cardiovascular
Other Interventional Solutions
Other Pulmonary Hypertension
COVID-19
Other Immunology
Details
Date
DARZALEX
Stelara
OTC
ELECTROPHYSIOLOGY
GENERAL
Tremfya
ADVANCED
Remicade
Skin health/Beauty
CONTACT LENSES/OTHER
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA
ERLEADA
IMBRUVICA
SPINE & OTHER
TRAUMA
SPINE,SPORTS & OTHER
ZYTIGA
Simponi/Simponi Aria
XARELTO
OPSUMIT
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
UPTRAVI
CARVYKTI
Abiomed
SPRAVATO
Baby Care
HIPS
OTHER NEUROSCIENCE
KNEES
SURGICAL
Oral Care
EDURANT/rilpivirine
Other
Shockwave Medical, Inc
Women's Health
PROCRIT/EPREX
VELCADE
Other Oncology
INVOKANA/INVOKAMET
RYBREVANT/LAZCLUZE
Wound Care and Other
CAPLYTA
CONCERTA/Methylphenidate
RISPERDAL CONSTA
TECVAYLI
ZYTIGA/abiraterone acetate
TALVEY
Other Infectious Diseases
other cardiovascular
Other Interventional Solutions
Other Pulmonary Hypertension
COVID-19
Other Immunology
Jan 1, 2018
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
4.19 B USD
7.71 B USD
4.82 B USD
0.00 USD
4.39 B USD
1.35 B USD
3.84 B USD
3.75 B USD
4.45 B USD
2.99 B USD
3.65 B USD
760.00 M USD
4.13 B USD
2.70 B USD
2.61 B USD
0.00 USD
2.47 B USD
2.24 B USD
2.35 B USD
1.64 B USD
2.18 B USD
1.09 B USD
0.00 USD
0.00 USD
0.00 USD
1.52 B USD
1.28 B USD
1.63 B USD
1.17 B USD
925.00 M USD
1.64 B USD
964.00 M USD
1.19 B USD
0.00 USD
901.00 M USD
552.00 M USD
408.00 M USD
413.00 M USD
795.00 M USD
0.00 USD
720.00 M USD
0.00 USD
622.00 M USD
642.00 M USD
0.00 USD
0.00 USD
0.00 USD
427.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
11.00 M USD
Jan 1, 2022
6.02 B USD
9.13 B USD
5.23 B USD
0.00 USD
5.19 B USD
2.13 B USD
4.62 B USD
3.19 B USD
4.54 B USD
3.44 B USD
4.02 B USD
1.29 B USD
4.37 B USD
0.00 USD
2.89 B USD
2.89 B USD
0.00 USD
2.28 B USD
2.44 B USD
1.82 B USD
2.08 B USD
1.24 B USD
0.00 USD
0.00 USD
0.00 USD
1.57 B USD
1.49 B USD
1.73 B USD
1.33 B USD
1.25 B USD
1.65 B USD
994.00 M USD
981.00 M USD
0.00 USD
917.00 M USD
479.00 M USD
0.00 USD
568.00 M USD
563.00 M USD
0.00 USD
739.00 M USD
0.00 USD
667.00 M USD
592.00 M USD
0.00 USD
2.30 B USD
0.00 USD
399.00 M USD
0.00 USD
0.00 USD
0.00 USD
2.39 B USD
24.00 M USD
Jan 1, 2023
9.74 B USD
10.86 B USD
0.00 USD
4.69 B USD
5.37 B USD
3.15 B USD
4.67 B USD
1.84 B USD
0.00 USD
3.70 B USD
4.12 B USD
2.39 B USD
3.26 B USD
0.00 USD
2.98 B USD
2.95 B USD
0.00 USD
2.20 B USD
2.37 B USD
1.97 B USD
1.85 B USD
1.58 B USD
500.00 M USD
1.31 B USD
0.00 USD
0.00 USD
1.56 B USD
1.55 B USD
1.46 B USD
1.37 B USD
0.00 USD
1.15 B USD
1.31 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
879.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
783.00 M USD
689.00 M USD
0.00 USD
887.00 M USD
0.00 USD
297.00 M USD
0.00 USD
356.00 M USD
0.00 USD
1.12 B USD
11.00 M USD
Jan 1, 2023
7.98 B USD
9.72 B USD
6.03 B USD
0.00 USD
5.12 B USD
2.67 B USD
4.57 B USD
2.34 B USD
4.35 B USD
3.54 B USD
4.14 B USD
1.88 B USD
3.78 B USD
0.00 USD
2.87 B USD
2.84 B USD
0.00 USD
2.18 B USD
2.47 B USD
1.78 B USD
1.94 B USD
1.32 B USD
0.00 USD
0.00 USD
0.00 USD
1.46 B USD
1.51 B USD
1.62 B USD
1.36 B USD
1.31 B USD
1.51 B USD
1.01 B USD
966.00 M USD
0.00 USD
904.00 M USD
0.00 USD
0.00 USD
571.00 M USD
448.00 M USD
0.00 USD
700.00 M USD
0.00 USD
644.00 M USD
485.00 M USD
0.00 USD
1.77 B USD
0.00 USD
318.00 M USD
0.00 USD
0.00 USD
0.00 USD
2.18 B USD
17.00 M USD
Jan 1, 2024
11.67 B USD
10.36 B USD
0.00 USD
5.27 B USD
5.36 B USD
3.67 B USD
4.49 B USD
1.61 B USD
0.00 USD
3.73 B USD
4.22 B USD
3.00 B USD
3.04 B USD
0.00 USD
3.05 B USD
2.93 B USD
0.00 USD
2.19 B USD
2.37 B USD
2.18 B USD
1.71 B USD
1.82 B USD
963.00 M USD
1.50 B USD
1.08 B USD
0.00 USD
1.64 B USD
1.18 B USD
1.55 B USD
1.41 B USD
0.00 USD
1.27 B USD
1.19 B USD
564.00 M USD
0.00 USD
0.00 USD
0.00 USD
931.00 M USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
641.00 M USD
0.00 USD
549.00 M USD
631.00 M USD
0.00 USD
214.00 M USD
380.00 M USD
0.00 USD
281.00 M USD
198.00 M USD
3.00 M USD
Jan 1, 2025
14.35 B USD
6.08 B USD
0.00 USD
5.63 B USD
5.56 B USD
5.16 B USD
4.58 B USD
1.77 B USD
0.00 USD
3.91 B USD
3.81 B USD
3.57 B USD
2.82 B USD
0.00 USD
3.15 B USD
2.85 B USD
0.00 USD
2.67 B USD
2.63 B USD
2.33 B USD
1.58 B USD
1.90 B USD
1.89 B USD
1.75 B USD
1.70 B USD
0.00 USD
1.67 B USD
1.05 B USD
1.59 B USD
1.56 B USD
0.00 USD
1.49 B USD
1.15 B USD
1.15 B USD
0.00 USD
0.00 USD
0.00 USD
376.00 M USD
0.00 USD
734.00 M USD
0.00 USD
700.00 M USD
584.00 M USD
0.00 USD
670.00 M USD
502.00 M USD
463.00 M USD
175.00 M USD
397.00 M USD
0.00 USD
209.00 M USD
0.00 USD
61.00 M USD

Johnson & Johnson Revenue by Segment (2/6)

  • 3 Years

  • 5 Years

  • Max

Xarelto
Details
Date
Xarelto
Jan 1, 2018
2.48 B USD
Jan 1, 2019
2.31 B USD
Jan 1, 2021
0.00 USD
Jan 1, 2022
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2023
0.00 USD
Jan 1, 2024
0.00 USD
Jan 1, 2025
0.00 USD

Johnson & Johnson Revenue by Segment (3/6)

  • 3 Years

  • 5 Years

  • Max

DARZALEX
Stelara
OTC
GENERAL
Tremfya
Beauty
ADVANCED
Remicade
CONTACT LENSES/OTHER
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA
IMBRUVICA
SPINE & OTHER
TRAUMA
ZYTIGA
Simponi/Simponi Aria
OPSUMIT
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
UPTRAVI
Baby Care
HIPS
OTHER NEUROSCIENCE
KNEES
SURGICAL
Oral Care
EDURANT/rilpivirine
Other
Women's Health
SPECIALTY
PROCRIT/EPREX
VELCADE
Other Oncology
INVOKANA/INVOKAMET
Wound Care and Other
CONCERTA/Methylphenidate
RISPERDAL CONSTA
Tremfaya
Other Infectious Diseases
TRACLEER
Other Immunology
Details
Date
DARZALEX
Stelara
OTC
GENERAL
Tremfya
Beauty
ADVANCED
Remicade
CONTACT LENSES/OTHER
INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA
IMBRUVICA
SPINE & OTHER
TRAUMA
ZYTIGA
Simponi/Simponi Aria
OPSUMIT
PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA
UPTRAVI
Baby Care
HIPS
OTHER NEUROSCIENCE
KNEES
SURGICAL
Oral Care
EDURANT/rilpivirine
Other
Women's Health
SPECIALTY
PROCRIT/EPREX
VELCADE
Other Oncology
INVOKANA/INVOKAMET
Wound Care and Other
CONCERTA/Methylphenidate
RISPERDAL CONSTA
Tremfaya
Other Infectious Diseases
TRACLEER
Other Immunology
Jan 1, 2018
2.03 B USD
5.16 B USD
2.48 B USD
4.56 B USD
0.00 USD
1.98 B USD
4.00 B USD
5.33 B USD
3.30 B USD
2.93 B USD
2.62 B USD
3.27 B USD
2.70 B USD
3.50 B USD
2.08 B USD
1.22 B USD
1.96 B USD
663.00 M USD
1.44 B USD
1.42 B USD
1.75 B USD
1.50 B USD
1.25 B USD
918.00 M USD
816.00 M USD
149.00 M USD
1.04 B USD
1.34 B USD
988.00 M USD
1.12 B USD
590.00 M USD
881.00 M USD
239.00 M USD
663.00 M USD
737.00 M USD
544.00 M USD
533.00 M USD
546.00 M USD
10.00 M USD
Jan 1, 2019
3.00 B USD
6.36 B USD
4.44 B USD
4.48 B USD
1.01 B USD
4.59 B USD
4.10 B USD
4.38 B USD
3.39 B USD
3.33 B USD
3.41 B USD
3.20 B USD
2.72 B USD
2.80 B USD
2.19 B USD
1.33 B USD
2.11 B USD
819.00 M USD
1.68 B USD
1.44 B USD
1.61 B USD
1.48 B USD
1.23 B USD
1.53 B USD
861.00 M USD
1.35 B USD
986.00 M USD
926.00 M USD
790.00 M USD
751.00 M USD
739.00 M USD
735.00 M USD
671.00 M USD
696.00 M USD
688.00 M USD
0.00 USD
441.00 M USD
341.00 M USD
10.00 M USD
Jan 1, 2021
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Johnson & Johnson Revenue by Segment (4/6)

  • Max

Innovative Medicine
MedTech
Details
Date
Innovative Medicine
MedTech
Jan 1, 2018
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
Jan 1, 2023
54.76 B USD
30.40 B USD
Jan 1, 2023
0.00 USD
0.00 USD
Jan 1, 2024
56.96 B USD
31.86 B USD
Jan 1, 2025
60.40 B USD
0.00 USD

Johnson & Johnson Revenue by Segment (5/6)

  • 3 Years

  • 5 Years

  • Max

Pharmaceutical
Medical Devices
Consumer
Details
Date
Pharmaceutical
Medical Devices
Consumer
Jan 1, 2018
0.00 USD
4.55 B USD
8.09 B USD
Jan 1, 2019
0.00 USD
25.96 B USD
13.90 B USD
Jan 1, 2021
45.57 B USD
0.00 USD
0.00 USD
Jan 1, 2022
52.08 B USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
52.56 B USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
0.00 USD
0.00 USD

Johnson & Johnson Revenue by Segment (6/6)

  • 3 Years

  • 5 Years

  • Max

Pharmaceutical
MedTech
Medical Devices
Consumer Health
Consumer
Details
Date
Pharmaceutical
MedTech
Medical Devices
Consumer Health
Consumer
Jan 1, 2018
2.57 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
42.20 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
22.96 B USD
0.00 USD
14.05 B USD
Jan 1, 2022
0.00 USD
0.00 USD
27.06 B USD
14.64 B USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
27.43 B USD
14.95 B USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
33.79 B USD
0.00 USD
0.00 USD
0.00 USD

Johnson & Johnson Revenue by Region

  • 3 Years

  • 5 Years

  • 10 Years

  • Max

Operating Segments
United States
U.S. Plans
Other Countries
Europe
Asia-Pacific, Africa
Western Hemisphere, excluding U.S.
Western Hemisphere excluding U.S
Details
Date
Operating Segments
United States
U.S. Plans
Other Countries
Europe
Asia-Pacific, Africa
Western Hemisphere, excluding U.S.
Western Hemisphere excluding U.S
Jan 1, 2018
0.00 USD
41.88 B USD
0.00 USD
39.70 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2019
0.00 USD
0.00 USD
42.10 B USD
39.96 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2021
0.00 USD
0.00 USD
43.13 B USD
39.45 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2022
0.00 USD
0.00 USD
47.16 B USD
46.62 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
46.44 B USD
38.72 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2023
0.00 USD
0.00 USD
48.58 B USD
46.36 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2024
0.00 USD
0.00 USD
50.30 B USD
38.52 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD
Jan 1, 2025
0.00 USD
53.75 B USD
0.00 USD
40.44 B USD
0.00 USD
0.00 USD
0.00 USD
0.00 USD

Johnson & Johnson Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Johnson & Johnson historical P/E ratio, EBIT multiple, and P/S ratio

Johnson & Johnson annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Johnson & Johnson shares outstanding

The number of shares of Johnson & Johnson was 2.44 B in 2025. This indicates how many shares Johnson & Johnson is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
2.67 B Stocks
Jan 1, 2022
2.66 B Stocks
Jan 1, 2023
2.43 B Stocks
Jan 1, 2024
2.43 B Stocks
Jan 1, 2025
2.44 B Stocks
Jan 1, 2026 (e)
2.44 B Stocks
Jan 1, 2027 (e)
2.44 B Stocks
Jan 1, 2028 (e)
2.44 B Stocks

Johnson & Johnson stock splits

In Johnson & Johnson's history, there have been no stock splits.

Johnson & Johnson Dividend History

37 years of dividend payments · 23 consecutive increases

YearAnnual DividendYoY ChangePayments
20261.30USDYTD—1×
Feb 24, 20261.30USD 0.0%1/1
20255.14USD↑ 4.7%4×
Feb 18, 20251.24USD 0.0%1/4
May 27, 20251.30USD↑ 4.8%2/4
Aug 26, 20251.30USD 0.0%3/4
Nov 25, 20251.30USD 0.0%4/4
20244.91USD↑ 4.5%4×
20234.70USD↑ 5.6%4×
20224.45USD↑ 6.2%4×
20214.19USD↑ 5.3%4×
20203.98USD↑ 6.1%4×
20193.75USD↑ 5.9%4×
20183.54USD↑ 6.6%4×
20173.32USD↑ 5.4%4×

Johnson & Johnson dividend history and estimates

In 2025, Johnson & Johnson paid a dividend amounting to 5.14 USD. Dividend means that Johnson & Johnson distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
4.19 USD
0.00 USD
Jan 1, 2022
4.45 USD
0.00 USD
Jan 1, 2023
4.70 USD
0.00 USD
Jan 1, 2024
4.91 USD
0.00 USD
Jan 1, 2025
5.14 USD
0.00 USD
Jan 1, 2026 (e)
1.30 USD
3.90 USD
Jan 1, 2027 (e)
0.00 USD
5.47 USD
Jan 1, 2028 (e)
0.00 USD
5.76 USD

Johnson & Johnson dividend payout ratio

In 2025, Johnson & Johnson had a payout ratio of 46.77%. The payout ratio indicates the percentage of the company's profits that Johnson & Johnson distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
53.59 %
Jan 1, 2022
66.07 %
Jan 1, 2023
32.50 %
Jan 1, 2024
84.72 %
Jan 1, 2025
46.77 %
Jan 1, 2026 (e)
44.51 %
Jan 1, 2027 (e)
42.51 %
Jan 1, 2028 (e)
40.16 %

Current Johnson & Johnson forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
12.30 %
Buy59.38 % (19)
Hold40.63 % (13)
Sell0.00 % (0)
12M Price Target
241.74
Last Price
260.81
Currency
USD
12M Return Potential
-7.31 %
LTM Return
0 %

Johnson & Johnson Earnings Calls

2024

Johnson & Johnson Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
7/15/20262.87USD25.29 BUSD2026 Q2
4/14/20262.70USD23.86 BUSD2026 Q1
1/21/20262.46USD24.40 BUSD2025 Q4
4/16/20242.66USD21.38 BUSD2024 Q1
1/23/20242.45USD21.21 BUSD2023 Q4
1/22/20242.69USD25.27 BUSD2023 Q4
7/17/20232.62USD24.71 BUSD2023 Q2
4/17/20232.60USD24.12 BUSD2023 Q1
1/24/20232.25USD24.27 BUSD2022 Q4
10/18/20222.50USD23.69 BUSD2022 Q3
...

EESG©

Eulerpool ESG Scorecard© for the Johnson & Johnson stock

81/100
87
Environment
93
Social
62
Governance
E

Environment

20
Scope 1 - Direct Emissions320,104
Scope 2 - Indirect emissions from purchased energy467,934
Scope 3 - Indirect emissions within the value chain6,865,589
Total CO₂ emissions788,038
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides—
Palm Oil
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees50.36
Percentage of women in management—
Percentage of Asian employees16.2
Share of Asian management19.8
Percentage of Hispanic/Latino employees9.9
Hispano/Latino Management share8
Percentage of Black employees7.5
Black Management Share6.4
Percentage of white employees63.8
White Management Share63.4
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Johnson & Johnson shareholder structure

% Name
9.71537%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
5.46626%
State Street Investment Management (US)
State Street Investment Management (US)
5.34138%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
2.49483%
Geode Capital Management, L.L.C.
Geode Capital Management, L.L.C.
1.51113%
JP Morgan Asset Management
JP Morgan Asset Management
1.41479%
State Farm Insurance Companies
State Farm Insurance Companies
...

Johnson & Johnson Executives and Management Board

JD

Mr. Joaquin Duato

(62)

Chairman of the Board, Chief Executive Officer · since 2016

Compensation24.30 M USD
JW

Mr. Joseph Wolk

(58)

Chief Financial Officer, Executive Vice President

Compensation12.62 M USD
TS

Mr. Tim Schmid

(55)

Executive Vice President, Worldwide Chairman of MedTech

Compensation11.86 M USD
JT

Ms. Jennifer Taubert

(61)

Executive Vice President, Worldwide Chairman, Innovative Medicine

Compensation11.19 M USD
PR

Prof. Dr. John Reed

(66)

Executive Vice President - Innovative Medicine, Research and Development

Compensation9.30 M USD

Johnson & Johnson Supply Chain

Johnson & Johnson Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
30 companies
#Name1M3M6M1Y2YTrend
1
Berkshire Hathaway B
Supplier
0.16
0.70
0.79
0.63
0.89
2
AbbVie
Supplier
0.07
0.71
0.80
0.63
0.80
3
Live Nation Entertainment
Supplier
0.38
-0.55
-0.12
0.01
0.77
4
Boston Scientific Corporation
Supplier
0.46
0.31
0.60
0.44
0.77
5
Eurofins Scientific
Supplier
-0.05
0.55
-0.34
-0.12
0.73
#Name1M3M6M1Y2YTrend
1
SourceBio International
Supplier
-0.11
-0.27
-0.34
-0.08
—
2
Apria, Inc.
0.05
0.83
0.25
-0.06
—
3
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.
0.51
—
—
—
—
4
Macfarlane Group
Supplier
0.31
0
-0.50
-0.39
—
5
Astellas Pharma Inc.
Supplier
0.27
-0.39
-0.03
—
—

Frequently asked questions about Johnson & Johnson

Johnson & Johnson operates under a diversified business model. The company is engaged in the development, manufacturing, and marketing of a wide range of healthcare products. Their business segments include pharmaceuticals, medical devices, and consumer health products. Johnson & Johnson is known for their innovative approach in creating advanced treatments and solutions for various health conditions and diseases. With a focus on research and development, they strive to provide high-quality products that improve the well-being of people around the world. Johnson & Johnson's commitment to delivering value to their customers and stakeholders drives their success in the global healthcare industry.

All fundamentals and in-depth analysis of Johnson & Johnson

Our stock analysis for Johnson & Johnson stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Johnson & Johnson. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Johnson & Johnson Stock
Johnson & Johnson Revenue→
Johnson & Johnson Stock
Johnson & Johnson Net Income→
Johnson & Johnson Stock
Johnson & Johnson P/E→
Johnson & Johnson Stock
Johnson & Johnson P/S→
Johnson & Johnson Stock
Johnson & Johnson EBIT→
Johnson & Johnson Stock
Johnson & Johnson Dividend→
Johnson & Johnson Stock
Johnson & Johnson Directors Dealings→
Johnson & Johnson Stock
Johnson & Johnson Stocks→
Johnson & Johnson Stock
Johnson & Johnson Market capitalization→
Johnson & Johnson Stock
Johnson & Johnson Debt→
Johnson & Johnson Stock
Johnson & Johnson Liabilities→
Johnson & Johnson Stock
Johnson & Johnson Equity→
Johnson & Johnson Stock
Johnson & Johnson AAQS→
Johnson & Johnson Stock
Johnson & Johnson Employees→
Johnson & Johnson Stock
Johnson & Johnson ROE→
Johnson & Johnson Stock
Johnson & Johnson ROA→
Johnson & Johnson Stock
Johnson & Johnson ROCE→
Johnson & Johnson Stock
Johnson & Johnson News→
Johnson & Johnson Stock
Johnson & Johnson Analyst Price Targets→

Health Stocks

Johnson Chemical Pharmaceutical Works CoJMS CoJoincare Pharmaceutical Group Industry CoJMolner ASJoinn Laboratories China CoJMDCJointJLKJointown Pharmaceutical Group CoJiuzhitang CoJourney MedicalJinyu Bio-Technology CoAll Stocks A–Z →